Search Results - "Burlot, Chloé"

Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro by Crosley, Powel, Farkkila, Anniina, Jenner, Adrianne L, Burlot, Chloé, Cardinal, Olivia, Potts, Kyle G, Agopsowicz, Kate, Pihlajoki, Marjut, Heikinheimo, Markku, Craig, Morgan, Fu, Yangxin, Hitt, Mary M

“…Granulosa cell tumors (GCT) constitute only ~5% of ovarian neoplasms yet have significant consequences, as up to 80% of women with recurrent GCT will die of…”
Get full text

Improving olaparib exposure to optimize adverse effects management by Sterlé, Marylise, Puszkiel, Alicja, Burlot, Chloé, Pereira, Eva, Bellesoeur, Audrey, De Percin, Sixtine, Beinse, Guillaume, Fumet, Jean-David, Favier, Laure, Niogret, Julie, Blanchet, Benoit, Royer, Bernard, Bengrine-Lefevre, Leïla, Schmitt, Antonin

“…Olaparib is an inhibitor of the human poly-(ADP-ribose)-polymerase enzymes (PARP1/2) needed to repair single-strand DNA breaks. It is used in breast, ovarian,…”
Get full text

Establishing combination PAC‐1 and TRAIL regimens for treating ovarian cancer based on patient‐specific pharmacokinetic profiles using in silico clinical trials by Cardinal, Olivia, Burlot, Chloé, Fu, Yangxin, Crosley, Powel, Hitt, Mary, Craig, Morgan, Jenner, Adrianne L.

“…Ovarian cancer is commonly diagnosed in its late stages, and new treatment modalities are needed to improve patient outcomes and survival. We have recently…”
Get full text